N-acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: Comprehensive meta-analysis

Catheterization and Cardiovascular Interventions

Volumn 64, Issue 4, 2005, Pages 471-479

  Duong, Michael H ^a   MacKenzie, Todd A ^b   Malenka, David J ^b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b NONE

Author keywords

Acute renal failure; Contrast nephropathy; Meta analysis; N acetylcysteine

Indexed keywords

ACETYLCYSTEINE; CONTRAST MEDIUM; CREATININE; IODIXANOL; IOHEXOL; IOPAMIDOL; IOPROMIDE; IOXILAN;

ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DRUG INDUCED DISEASE; FLUID THERAPY; HEART CATHETERIZATION; HEMODIALYSIS; HUMAN; KIDNEY BLOOD FLOW; KIDNEY DISEASE; LENGTH OF STAY; META ANALYSIS; MORBIDITY; MORTALITY; PROSPECTIVE STUDY; RADIOCONTRAST INDUCED NEPHROPATHY; REGRESSION ANALYSIS; REHYDRATION; RISK REDUCTION; TREATMENT OUTCOME;

ACETYLCYSTEINE; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, ACUTE; KIDNEY FUNCTION TESTS; MALE; PRIMARY PREVENTION; RADIOPHARMACEUTICALS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED;

EID: 16244412258     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.20342     Document Type: Article

References (69)

1. Parfrey PS, Griffiths SM, Barrett BJ, Paul MD, Genge M, Withers J, Farid N, McManamon PJ. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both: a prospective controlled study. N Engl J Med 1989;320:143-149.
2. Curhan GC. Prevention of contrast nephropathy. JAMA 2003;289:606-608.
3. Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol 2000;11:177-182.
4. Weisbord S, Bruns F, Saul M, Chang C, Palevsky P. The high cost of acute renal failure following the administration of intravenous contrast media in hospitalized patients. J Am Soc Nephrol 2002;13:447A.
5. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality: a cohort analysis. JAMA 1996;275:1489-1494.
6. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ. Singh M, Bell MR, Barsness GW, Mathew V, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105:2259-2264.
7. Katholi R, Woods WT Jr, Taylor G, Deitrick C, Womack K. Katholi C, McCann W. Oxygen free radicals and contrast nephropathy. Am J Kidney Dis 1998;32:64-71.
8. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-184.
9. Clarke M, Oxman A, editors. Cochrane reviewers' handbook 4.2.0. Oxford: Update. Software.
10. Fleiss J. 1981. Statistical methods for rates and proportions. New York: John Wiley and Sons, p 161-165.
11. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
12. Jadad A, Caroll D, Jenkinson C, Reynolds D, Gavaghan D, McQuay J. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
13. Thompson S, Sharp S. Explaining heterogeniety in meta-analysis: a comparison of methods. Stat Med 1999;18:2693-2708.
14. Light R, Pillemer D. 1984. Summing up: the science of reviewing research. Cambridge, MA: Harvard University Press.
15. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997;315:629-634.
16. Begg C, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-1101.
17. Diaz-Sandoval L, Kosowsky B, Losordo D. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002;89:356-358.
18. Briguori C, Manganelli F, Scarpato P, Elia P, Goilia B, Riviezzo G, Lepore S, Librera M, villari B, Colombo A, et al. Acetylcysteine and contrast agent-associated nephropathy. J Am Coll Cardiol 2002;40:298-303.
19. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 2002;40:1383-1388.
20. Allaqaband S, Tumuluri R, Malik AM, Gupta A, Volkert P, Shalev Y, Bajwa TK. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 2002;57:279-283.
21. Durham JD, Caputo C, Dokko J, Zaharakis T, Pahlavan M, Keltz J, Dutka P, Marzo K, Maesaka JK, Fishbane S. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002;62:2202-2207.
22. Kay J, Chow WH, Chan TM, Lo SK, Kwok OH, Yip A, Fan K, Lee CH, Lam WF. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 2003;289:553-558.
23. Boccalandro F, Amhad M, Smalling RW, Sdringola S. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter Cardiovasc Interv 2003;58:336-341.
24. Le Feuvre C, El Mahmoud R, Helft G, Beygui F, Batisse J, Metzger J. Prevention of renal function worsening after coronary angioplasty: the role of acetylcysteine. J Am Coll Cardiol 2003;41(Suppl 6):18A.
25. Loutrianakis E, Stella D, Hussain A, Lewis B, Lowell S, Sochanski M, Leya F, Grassman E. Randomized comparison of fenoldopam and N-acetylcysteine to saline in the prevention of radio-contrast induced nephropathy. J Am Coll Cardiol 2003;41(Suppl 6):327A.
26. Oldemeyer J, Biddle W, Wurdeman R, Mooss A, Cichowski E, Hilleman D. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Heart J 2003;146:E23.
27. Tadros GM, Mouhayar EN, Akinwande AO, Campbell B, Wood C, Blankenship JA. Prevention of radiocontrast-induced nephropathy with N-acetylcysteine in patients undergoing coronary angiography. J Invas Cardiol 2003;15:311-314.
28. MacNeill B, Harding S, Bazari H, Patton K, Colon-Hernandez P, deJoseph D, Jang I. Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography. Catheter Cardiovasc Interv 2003;60:458-461.
29. Adamian M, Moussa I, Mehran R. The role of mucomyst administration prior to precutaneous interventions on renal function in patients with chronic renal failure. J Am Coll Cardiol 2002;39(Suppl 5A):1A.
30. Bader B, Bergen E, Rossmann S. Prevention of contrast media-induced acute renal failure in patients with severe impaired renal function: theophylline versus N-acetylcysteine (NAC). J Am Soc Nephrol 2002;13:447A.
31. Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, Knight CJ. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 2003;41:2114-2118.
32. Briguori C, Colombo A, Violante A, Balestrieri P, Goilia B, Scarpato P, Elia P, Lepore S, Ricciardelli B. High versus low dose of acetylcysteine to prevent contrast agents associated with nephrotissicity. J Am Coll Cardiol 2003;41(Suppl 6):39A.
33. Goldenberg I, Shechter M, Matetzki S, Jonas M, Adam M, Pres H, Elian D, Agranat O, Schwmmental E, Guetta V. Oral acetyl-cysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography: a randomized controlled trial and review of the current literature. Eur Heart J 2004;25:212-218.
34. Gill NK, Piccione EA, Vido D, Clark BA, Shannon RP. The role of acetylcysteine in preventing contrast-induced nephropathy following cardiac catheterization in patients with acute and chronic renal failure. J Am Coll Cardiol 2003;41(Suppl 6):23A.
35. Mouhayar E, Tadros G, Akinwande A, Campbell B, Blankenship J. Prevention of contrast-induced renal dysfunction with acetyl-cysteine in patients undergoing coronary angiography. J Am Coll Cardiol 2002;39(Suppl):5A.
36. Kanderian A, Abdelhadi RH, Bhatt DL, Schneider J, Chung MK. Hydration versus N-acetylcysteine for protection of renal function in patients with renal insufficiency undergoing percutaneous coronary intervention. J Am Coll Cardiol 2003;41(Suppl 6):63A.
37. Nogareda GJ. Oral N-acetylcysteine administred immediately prior to routine percutaneous coronary procedures ameliorates contrast-induced nephropathy. J Am Coll Cardiol 2003;41(Suppl 6):62A.
38. Vallero A, Cesano G, Pozzato M, Garbo R, Minelli M, Quarello F, Formica M. Nefropatia da contrasto in cardiologia interventistica: assenza di vantaggi con impiego profilattico di N-acetilcisteina. G Ital Nefrol 2002;19:529-533.
39. Efrati S, Dishy V, Averbukh M, Blatt A, Krakover R. Weisgarten J, Morrow J, Stein M, Golik A. The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography. Kidney Int 2003;64:2182-2187.
40. Raven Q, Walton T, Howe A, Macon E. Role of acetylcysteine in the prevention of contrast-media-induced nephrotoxicity. Am J Health Syst Pharm 2003;60:2232-2235.
41. Azmus A, Manica A, Duro K. The effect of N-acetylcysteine in renal function in patients undergoing coronary intervention. Am J Cardiol 2002;90(6 Suppl):144H.
42. Gomes V, Caramori P, Lasevitch R, Brizolara A, Nery P, Araujo A. Prevention of contrast-induced nephropathy with N-acetylcysteine in patients undergoing coronary angiography: a randomized multicenter trial. Circulation 2003;108(Suppl 17):460.
43. Nguyen-Ho P, Dzavik V, Seidelin P, Daly P, Ross J, McLaughlin P, Ing D, Barolet A, Schwartz L, Miner S. N-acetylcysteine does not prevent long-term clinical events despite reducing periprocedural contrast-associated nephropathy. Circulation 2003;108(Suppl 17):445.
44. Ochoa A, Isayneko Y, Pellizzon G, Addala S, Chowdhury P, Boura J, Rempinksi D, Grines C, O'Neill W, Kahn J. Abbreviated dosing of N-acetylcysteine prevents contrast induced acute renal failure after coronary angiography and intervention. Circulation 2002;106(Suppl 2):136.
45. Webb JG, Pate GE, Humphries KH, Buller CE, Shalansky S, Al Shamari A, Sutander A, Williams T, Fox RS, Levin A. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J 2004;148:422-429.
46. Miner SE, Dzavik V, Nguyen-Ho P, Richardson R, Mitchell J, Atchison D, Seidelin P, Daly P, Ross J, McLaughlin PR, et al. N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up. Am Heart J 2004;148:690-695.
47. Fung JW, Szeto CC, Chan WW, Kum LC, Chan AK, Wong JT, Wu EB, Yip GW, Chan JY, Yu CM, et al. Effect of N-acetyl-cysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial. Am J Kidney Dis 2004;43:801-808.
48. Pate GE, Humphries KH, Shamari AA, Williams T, Fox RS, Buller CE, Levin A, Carere RG, Vaderah S, Webb JG. Intravenous acetylcysteine in the prevention of contrast induced nephropathy following coronary angiography. Circulation 2003;108(Suppl 17):445.
49. Rudnick M, Goldfarb S, Wexler L. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. Kidney Int 1995;47:254.
50. Lautin E, Freeman N, Schoenfeld A. Radiocontrast-associated renal dysfunction: a comparison of lower-osmolality and conventional high-osmolality and conventional high-osmolality contrast media. Am J Radiol 1991;157:59.
51. Barrett BJ, Parfrey PS, Vavasour HM, McDonald J, Kent G, Hefferton D, O'Dea F, Stone E, Reddy R, McManamon PJ. Contrast nephropathy in patients with impaired renal function: high versus low osmolar media. Kidney Int 1992;41:1274-1279.
52. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994;331:1416-1420.
53. Stevens MA, McCullough PA, Tobin KJ, Speck JP, Westveer DC, Guido-Allen DA, Timmis GC, O'Neill WW. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the PRINCE study. J Am Coll Cardiol 1999;33:403-411.
54. Kurnik B, Allgren R, Center F. Prospective study of atrial natrietic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 1998;31:674.
55. Gupta R, Kapoor A, Tewari S, Sinha N, Sharma R. Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study. Ind Heart J 1999;51:521-526.
56. Abizaid A, Clark C, Mintz G. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insuffiency. Am J Cardiol 1998;83:260-263.
57. Koch J, Plum J, Grabensee B, Modder U. Prostaglandin E1: a new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media? Nephrol Dial Transplant 2000;15:43-49.
58. Seyess C, Foote E. Calcium-channel blockers for prophylaxis of radiocontrast-associated nephrotoxicity. Ann Pharmacother 1995;29:187-188.
59. Marenzi G, Bartorelli AL, Lauri G, Assanelli E, Grazi M, Campodonico J, Marana I. Continuous veno-venous hemofiltration for the treatment of contrast-induced acute renal failure after percutaneous coronary interventions. Catheter Cardiovasc Interv 2003;58:59-64.
60. Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, Marsch S, Roskamm H. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002;162:329-336.
61. Baker C. Prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 2003;57:532-538.
62. Cox C, Tsikouris J. Preventing contrast nephropathy: what is the best strategy? a review of the literature. J Clin Pharmacol 2004;44:327-337.
63. Heyman S, Goldfarb M, Shina A, Karmeli F, Rosen S. N-acetyl-cysteine ameliorates renal microcirculation: studies in rats. Kidney Int 2003;63:634-641.
64. Marenzi G, Marana I, Lauri G, Assanelli E, Grazi M, Campodonico J, Trabattoni D, Fabbiocchi F, Montorsi P, Bartorelli AL. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 2003;349:1333-1340.
65. Birck R, Krzossok S, Markowetz F, Schnulle P, van der Woude FJ, Braun C. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003;362:598-603.
66. Isenbarger D, Kent S, O'Malley P. Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol 2003;92:1454-1458.
67. Alonso A, Lau J, Jaber BL, Weintraub A, Sarnak MJ. Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. Am J Kidney Dis 2004;43:1-9.
68. Kshirsagar A, Poole C, Mottl A, Shoham D, Franceschini N, Tudor G, Agrawal M, Denu-Ciocca C, Ohman E, Finn W. N-acetylcsyteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. J Am Soc Nephrol 2004;15:761-769.
69. Kahlon J, Moser L, Rosman H, Nordstrom C, Zafar A, Khairullah Q, Schreiber T, LaLonde T, Gardin J, Yamasaki H. Effectiveness of N-acetylcysteine for the prevention of radiocontrast-induced nephropathy: is the jury still out? Circulation 2002;106:691.